Literature DB >> 8790094

Fibrovascular tissue in bilateral juxtafoveal telangiectasis.

D Park1, H Schatz, H R McDonald, R N Johnson.   

Abstract

OBJECTIVE: To study the natural history and retinal findings associated with the intraretinal and subretinal fibrovascular tissues that develop in the late phases of bilateral juxtafoveal telangiectasis.
METHODS: The records of 10 patients (11 eyes) with bilateral juxtafoveal telangiectasis who developed these fibrovascular tissues were examined.
RESULTS: Throughout the follow-up period (average 44 months), only 2 eyes (18%) lost 2 or more lines of vision; the final visual acuities were similar for the eyes both with and without fibrovascular tissues. Sixty-four percent of fibrovascular tissues showed little to no growth. Eyes with fibrovascular tissue commonly had retinal pigment epithelial hyperplasia (72%), draining retinal venules (82%), and retinal vascular distortion (64%).
CONCLUSIONS: Fibrovascular tissues of bilateral juxtafoveal telangiectasis have little proliferative potential and minimal effects on visual acuity. Nevertheless, these fibrovascular tissues do remodel over time, leading to retinal vascular distortion. Given these benign findings, the role of laser photocoagulation treatment of these tissues is questionable.

Entities:  

Mesh:

Year:  1996        PMID: 8790094     DOI: 10.1001/archopht.1996.01100140294006

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  4 in total

1.  Clinicopathological correlation of deep retinal vascular anomalous complex in age related macular degeneration.

Authors:  B A Lafaut; S Aisenbrey; C Vanden Broecke; K U Bartz-Schmidt
Journal:  Br J Ophthalmol       Date:  2000-11       Impact factor: 4.638

2.  Idiopathic juxtafoveolar retinal telangiectasis: a current review.

Authors:  Sawsan R Nowilaty; Hanan N Al-Shamsi; Wajeeha Al-Khars
Journal:  Middle East Afr J Ophthalmol       Date:  2010-07

Review 3.  Macular telangiectasia type 2.

Authors:  Peter Charbel Issa; Mark C Gillies; Emily Y Chew; Alan C Bird; Tjebo F C Heeren; Tunde Peto; Frank G Holz; Hendrik P N Scholl
Journal:  Prog Retin Eye Res       Date:  2012-12-03       Impact factor: 21.198

4.  [Therapeutic approaches for macular telangiectasia type 2: status quo and perspectives].

Authors:  F G Holz; T F C Heeren; E Krüger; M Zeimer; D Pauleikhoff; P Charbel Issa
Journal:  Ophthalmologe       Date:  2014-09       Impact factor: 1.059

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.